CRIS, coming up shorted.
Curis (CRIS) is one of the most heavily shorted biotech stocks. The shorts profited while management secured loans with royalties on the company's only marketed product. Stock offerings and a temporary FDA hold on a dosing study hurt, too. The FDA hold was removed, but the recent change in CEOs took a long time so now debt and the stock's price obstruct access to product development capital. The stock price is driving the company's fundamentals.